Old and New Dopamine Agonists in Parkinson's Disease: a Reappraisal. Proceedings of the LIMPE Seminar, 26-28 February, Pisa, Italy, 2009.

Old and new dopamine agonists in Parkinson's disease. Proceedings of an international congress. Pisa, Italy, December 1993.

P 124: Decrease Signs Parkinson`s Disease with DOPAMINE in Apple

After Alzheimer's disease, Parkinson's disease is the most common nerve-damaging disease. Parkinson's is a progressive and chronic disease where cells secrete dopamine-cut black flesh and in the absence of dopamine in the brain destroyed the irregular body movements. Man eats the food that causes the formation of the neurotransmitters. Tthree neurotransmitters: dopamine, serotonin, norepinephri...

Improvement of diagnostic accuracy of Parkinson's disease on I-123-ioflupane single photon emission computed tomography (123I FP-CIT SPECT) using new Japanese normal database

Objective(s): I-123-ioflupane single photon emission computed tomography (FP-CIT-SPECT) has been used to assess dopamine transporter (DAT) loss in Parkinson's disease. The specific binding ratio (SBR), a quantitative parameter of DAT density in the striatum, may be affected by differences in age, sex, and SPECT system. The purpose of this study was to evaluate the util...

P 48: Pioglitazone in Early Parkinson: A Review Study

More than 10 million people worldwide are living with Parkinson’s disease (PD). The ages of people who have Parkinson are variable, usually between 50 and 80 years, the average of them is 55 years old. The symptoms of PD are progressive, and within 10 to 20. It happens when dopaminergic neurons were being degenerate. Peripheral and central inflammatory and oxidative stress pathways play a...

Reward-learning and the novelty-seeking personality: a between- and within-subjects study of the effects of dopamine agonists on young Parkinson's patients.

Parkinson's disease is characterized by the degeneration of dopaminergic pathways projecting to the striatum. These pathways are implicated in reward prediction. In this study, we investigated reward and punishment processing in young, never-medicated Parkinson's disease patients, recently medicated patients receiving the dopamine receptor agonists pramipexole and ropinirole and healthy control...